Mycobacterium

Bruker Announces Share Purchase Agreement to Acquire Molecular Diagnostics Innovator ELITechGroup

Retrieved on: 
Wednesday, February 28, 2024

This put option has now been exercised, and the parties have entered into a binding share purchase agreement.

Key Points: 
  • This put option has now been exercised, and the parties have entered into a binding share purchase agreement.
  • ELITechGroup, with over 500 employees and over 40 active patents, develops and commercializes innovative, proprietary molecular diagnostic (MDx) systems and assays, as well as niche biomedical systems and microbiology products.
  • Establishing this unique business within Bruker - a well-respected global life-science tools and specialty diagnostics company - provides an exciting opportunity to further grow our molecular diagnostics, microbiology and biomedical systems portfolios.
  • Upon closing, ELITech is expected to be a stand-alone business within Bruker’s Microbiology and Infection Diagnostics division, as a part of the Bruker CALID Group.

Tuberculosis isn't just a historical disease. Here's how it spreads and who is at risk

Retrieved on: 
Tuesday, October 17, 2023

Tuberculosis is often seen as a threat of the past. But it remains a significant concern worldwide, with international travel spreading the disease. While tuberculous is rare in Australia, and we no longer routinely vaccinate against it, clusters of cases in South Australia over the past 17 months have put health authorities on alert. So what exactly is tuberculosis, how is it treated and what is Australia doing to prevent its transmission? It starts as a respiratory infection Tuberculosis, caused by the bacterium Mycobacterium tuberculosis, starts as a respiratory infection when inhaled.

Key Points: 


Tuberculosis is often seen as a threat of the past. But it remains a significant concern worldwide, with international travel spreading the disease. While tuberculous is rare in Australia, and we no longer routinely vaccinate against it, clusters of cases in South Australia over the past 17 months have put health authorities on alert. So what exactly is tuberculosis, how is it treated and what is Australia doing to prevent its transmission?

It starts as a respiratory infection

    • Tuberculosis, caused by the bacterium Mycobacterium tuberculosis, starts as a respiratory infection when inhaled.
    • Once in the lungs, the immune system responds by forming granulomas, clusters of immune cells (mainly macrophages and T cells), in an attempt to contain the infection.

Early treatment is key

    • Early diagnosis and treatment reduces the infectious period and helps prevent spreading the disease to others.
    • Delayed treatment can lead to complications such as lung damage and scarring; damage to the bones, kidneys, lymph nodes and central nervous system; and infection in the brain and spinal cord.
    • Antibiotic treatment, often involving multiple drugs, is highly effective at eliminating the bacteria.

Tackling drug-resistant bacteria

    • The Mycobacterium tuberculosis bacteria can quickly become resistant to antibiotics, so routine treatment includes multiple antibiotics which increases adverse effects.
    • The emergence of drug-resistant tuberculosis strains is a major concern because it makes treatment significantly more challenging and costly.

Who is susceptible to tuberculosis?

    • Children are also at greater risk of tuberculosis, as their immune systems are still developing.
    • However, the World Health Organization estimates 11% of the 10.6 million tuberculosis cases worldwide are in children.
    • Some 14% of all tuberculosis-related deaths occur in children under 15 years old.

What can we do about TB?

    • The Bacille Calmette-Guérin vaccine provides partial protection, primarily against severe forms of tuberculosis.
    • It’s not routinely given in Australia because we’re not considered a high-risk country, but it’s given in local regions with tuberculosis outbreaks.
    • Visa applicants aged 11 years and over must have a chest X-ray for evidence of active tuberculosis.

AN2 Therapeutics commences Phase 3 Part of Phase 2/3 Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium complex (MAC) Lung Disease

Retrieved on: 
Wednesday, September 13, 2023

The Phase 2/3 clinical trial is expected to support regulatory filings for approval in the U.S. and Japan.

Key Points: 
  • The Phase 2/3 clinical trial is expected to support regulatory filings for approval in the U.S. and Japan.
  • “Completing Phase 2 enrollment and initiating Phase 3 in this important clinical trial are significant milestones for AN2 and the patients we intend to serve.
  • There is currently no approved oral therapy for MAC lung disease.
  • This double-blind, placebo-controlled superiority trial uses an adaptive design to evaluate the safety and efficacy of epetraborole in patients with treatment-refractory MAC lung disease.

Is it okay to kiss your pet? The risk of animal-borne diseases is small, but real

Retrieved on: 
Monday, September 4, 2023

Pet ownership is at an all-time high, with a recent survey finding 69% of Australian households have at least one pet.

Key Points: 
  • Pet ownership is at an all-time high, with a recent survey finding 69% of Australian households have at least one pet.
  • We spend an estimated A$33 billion every year on caring for our fur babies.
  • But some, such as pregnant people and those with weakened immune systems, are at greater risk of getting sick from animals.

What diseases can pets carry?

    • Infectious diseases that move from animals to humans are called zoonotic diseases or zoonoses.
    • Zoonoses can be transmitted directly from pets to humans, such as through contact with saliva, bodily fluids and faeces, or indirectly, such as through contact with contaminated bedding, soil, food or water.
    • Both dogs and cats are also reservoirs for methicillin-resistant bacterium Staphylococcus aureus (MRSA), with close contact with pets identified as an important risk factor for zoonotic transmission.
    • Read more:
      Cats carry diseases that can be deadly to humans, and it's costing Australia $6 billion every year

Birds, turtles and fish can also transmit disease

    • Pet birds can occasionally transmit psittacosis, a bacterial infection which causes pneumonia.
    • Contact with pet turtles has been linked to Salmonella infections in humans, particularly in young children.
    • Even pet fish have been linked to a range of bacterial infections in humans, including vibriosis, mycobacteriosis and salmonellosis.
    • Close contact with animals – and some behaviours in particular – increase the risk of zoonotic transmission.

What should I do if I’m worried about catching a disease from my pet?


    There are a number of good hygiene and pet husbandry practices that can reduce your risk of becoming sick. These include:
    It is especially important for those who are at a higher risk of illness to take precautions to reduce their exposure to zoonotic pathogens. And if you’re thinking about getting a pet, ask your vet which type of animal would best suit your personal circumstances.

    Read more:
    One in three people are infected with _Toxoplasma_ parasite – and the clue could be in our eyes

Researchers discover new weapon against antibiotic resistance --it also fights malaria

Retrieved on: 
Thursday, June 29, 2023

MIAMI, June 29, 2023 /PRNewswire/ -- FIU scientists discovered the first and only known natural arsenic-containing antibiotic to fight antibiotic resistance.

Key Points: 
  • MIAMI, June 29, 2023 /PRNewswire/ -- FIU scientists discovered the first and only known natural arsenic-containing antibiotic to fight antibiotic resistance.
  • Now, research reveals it can stop transmission of a deadly disease spreading in the U.S. for the first time in 20 years: malaria.
  • Collaborating with malaria researchers in the College of Arts, Sciences & Education , they've recently also found AST prevents Plasmodium falciparum, the parasite that causes malaria, from infecting mosquitoes — unlike other current antimalarial drugs.
  • When FIU researchers tested AST on liver, kidney and intestinal cells, AST targeted the malaria parasite lurking in human cells, but didn't damage the cells themselves.

Bergen Prepares to Host International Conference on Hansen's Disease Marking 150 Years Since the Discovery of the Leprosy Bacillus

Retrieved on: 
Monday, June 19, 2023

The conference, which will be held in the city where Norwegian Dr. Gerhard Armauer Hansen made his groundbreaking finding, will also be streamed online.

Key Points: 
  • The conference, which will be held in the city where Norwegian Dr. Gerhard Armauer Hansen made his groundbreaking finding, will also be streamed online.
  • Many countries and international organizations, led by the World Health Organization, now aim to achieve zero leprosy—zero disease, zero disability and zero discrimination—.
  • Achieving this goal will require close collaboration between partners, which the Bergen meeting aims to foster.
  • The Bergen International Conference on Hansen's Disease: 150 Years Since the Discovery of the Leprosy Bacillus brings together key stakeholders in the leprosy field for sessions focused on medical challenges, human rights and dignity, and history preservation—the three pillars on which the Sasakawa Leprosy (Hansen's Disease) Initiative structures its activities against the disease.

Bruker Introduces New Mycobacteria and Fungi IVD Solutions for MALDI Biotyper®, and a Novel LiquidArray® Gastrointestinal Syndromic Panel

Retrieved on: 
Friday, April 14, 2023

The new MBT Mycobacteria IVD Kit offers a user-friendly, dedicated sample preparation method for mycobacteria cultivated in liquid as well as on solid media.

Key Points: 
  • The new MBT Mycobacteria IVD Kit offers a user-friendly, dedicated sample preparation method for mycobacteria cultivated in liquid as well as on solid media.
  • The MBT Mycobacteria IVD Kit further simplifies the workflow for identification of nontuberculous mycobacteria by MALDI-TOF MS and reduces hands-on time.
  • The new LiquidArray® Gastrointestinal is a syndromic panel that enables the simultaneous detection of up to 26 pathogens causing gastroenteritis.
  • The new LiquidArray® Gastrointestinal is a next-generation syndromic panel with amazing pathogen coverage.

Qurient Co. Ltd. and TB Alliance Announce Exclusive License Agreement for Telacebec (Q203), a New Anti-Tuberculosis Agent

Retrieved on: 
Friday, February 3, 2023

SEONGNAM-SI, South Korea and NEW YORK, Feb. 3, 2023 /PRNewswire/ -- Qurient Co. Ltd. ("Qurient", KRX: 115180), a clinical-stage biotechnology company based in South Korea, and TB Alliance, a not-for-profit organization dedicated to the discovery, development and delivery of better, faster-acting and affordable tuberculosis drugs, announced today that they have entered into a license agreement to develop and commercialize telacebec (Q203), a first-in-class orally available cytochrome bc1 inhibitor for the treatment of tuberculosis (TB) and other non-tuberculosis mycobacterium infections.

Key Points: 
  • Under the terms of the license agreement TB Alliance obtains the exclusive worldwide license (except for South Korea, Russia and the Commonwealth of Independent States (CIS) countries) to develop and commercialize telacebec for the treatment of tuberculosis and some non-tuberculosis mycobacteria (NTM) infections.
  • We believe telacebec will greatly contribute to the global efforts to combating the TB pandemic, which remains a serious public health challenge worldwide.
  • Our partnership with the TB Alliance will accelerate the widespread availability of telacebec and bring it to those in need."
  • Mel Spigelman, MD, President and CEO of TB Alliance, said "TB Alliance is excited to partner with Qurient to bring about the next generation of TB cures.

Qurient Co. Ltd. and TB Alliance Announce Exclusive License Agreement for Telacebec (Q203), a New Anti-Tuberculosis Agent

Retrieved on: 
Friday, February 3, 2023

SEONGNAM-SI, South Korea and NEW YORK, Feb. 3, 2023 /PRNewswire/ -- Qurient Co. Ltd. ("Qurient", KRX: 115180), a clinical-stage biotechnology company based in South Korea, and TB Alliance, a not-for-profit organization dedicated to the discovery, development and delivery of better, faster-acting and affordable tuberculosis drugs, announced today that they have entered into a license agreement to develop and commercialize telacebec (Q203), a first-in-class orally available cytochrome bc1 inhibitor for the treatment of tuberculosis (TB) and other non-tuberculosis mycobacterium infections.

Key Points: 
  • Under the terms of the license agreement TB Alliance obtains the exclusive worldwide license (except for South Korea, Russia and the Commonwealth of Independent States (CIS) countries) to develop and commercialize telacebec for the treatment of tuberculosis and some non-tuberculosis mycobacteria (NTM) infections.
  • We believe telacebec will greatly contribute to the global efforts to combating the TB pandemic, which remains a serious public health challenge worldwide.
  • Our partnership with the TB Alliance will accelerate the widespread availability of telacebec and bring it to those in need."
  • Mel Spigelman, MD, President and CEO of TB Alliance, said "TB Alliance is excited to partner with Qurient to bring about the next generation of TB cures.

Pace® Aerobiology Receives AIHA EMLAP Accreditation for Washington State Laboratory

Retrieved on: 
Wednesday, February 8, 2023

MINNEAPOLIS, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Aerobiology, part of the Pace® Analytical Services laboratory network, today announced that its Seattle, Washington, laboratory has achieved accreditation from the American Industrial Hygiene Association (AIHA) for its Environmental Microbiology Laboratory Accreditation Program (EMLAP).

Key Points: 
  • MINNEAPOLIS, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Aerobiology, part of the Pace® Analytical Services laboratory network, today announced that its Seattle, Washington, laboratory has achieved accreditation from the American Industrial Hygiene Association (AIHA) for its Environmental Microbiology Laboratory Accreditation Program (EMLAP).
  • The association manages several accreditation programs, including EMLAP, which was developed specifically for microbiology labs providing microbiology testing of air, fluids, and bulk samples collected from various sources including schools, hospitals, and work environments.
  • This accreditation ensures our customers meet their regulatory requirements on their important projects," notes Greg Whitman, president of Pace® Analytical Services.
  • Within the Pace® nationwide network of over 100 laboratories and service centers, 11 are Pace® Aerobiology locations offering microbiology testing and analysis capabilities.